sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Diabetic Macular Edema (DME): Market Assessment, Epidemiology & Market Forecast-2028

Diabetic Macular Edema (DME): Market Assessment, Epidemiology & Market Forecast-2028

Home / Categories / Healthcare
Diabetic Macular Edema (DME): Market Assessment, Epidemiology & Market Forecast-2028
Diabetic Macular Edema (DME): Market...
Report Code
RO1/114/2175

Publish Date
01/Mar/2019

Pages
100-120
PRICE
$ 4500/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 8000/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
1. Report Introduction
2. Diabetic Macular Edema (DME) Market Overview at Glance
3. Disease Background and Overview: Diabetic Macular Edema (DME)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnostic Landscape
3.6.1. Diagnostic Practices
3.6.2. Diagnostic Criteria
3.6.3. Diagnostic Recommendations
3.7. Treatment Landscape
3.7.1. Current Treatment Practices
3.7.2. Treatment Algorithm
3.7.3. Treatment Recommendations
4. Diabetic Macular Edema (DME) Epidemiology
4.1. Key Findings
4.2. Assumptions & Rationale
4.3. 7MM Epidemiology
5. Epidemiology of Diabetic Macular Edema (DME) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of Diabetic Macular Edema (DME)
5.1.3. Sub-Type Specific cases of Diabetic Macular Edema (DME)*
5.1.4. Sex- Specific Cases of Diabetic Macular Edema (DME)*
5.1.5. Diagnosed Cases of Diabetic Macular Edema (DME)
5.1.6. Treatable Cases of Diabetic Macular Edema (DME)
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent/Incident Cases of Diabetic Macular Edema (DME)
5.2.3. Sub-Type Specific cases of Diabetic Macular Edema (DME)*
5.2.4. Sex- Specific Cases of Diabetic Macular Edema (DME)*
5.2.5. Diagnosed Cases of Diabetic Macular Edema (DME)
5.2.6. Treatable Cases of Diabetic Macular Edema (DME)
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent/Incident Cases of Diabetic Macular Edema (DME)
5.3.3. Sub-Type Specific cases of Diabetic Macular Edema (DME)*
5.3.4. Sex- Specific Cases of Diabetic Macular Edema (DME)*
5.3.5. Diagnosed Cases of Diabetic Macular Edema (DME)
5.3.6. Treatable Cases of Diabetic Macular Edema (DME)
5.4. United Kingdom
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of Diabetic Macular Edema (DME)
5.4.3. Sub-Type Specific cases of Diabetic Macular Edema (DME)*
5.4.4. Sex- Specific Cases of Diabetic Macular Edema (DME)*
5.4.5. Diagnosed Cases of Diabetic Macular Edema (DME)
5.4.6. Treatable Cases of Diabetic Macular Edema (DME)
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of Diabetic Macular Edema (DME)
5.5.3. Sub-Type Specific cases of Diabetic Macular Edema (DME)*
5.5.4. Sex- Specific Cases of Diabetic Macular Edema (DME)*
5.5.5. Diagnosed Cases of Diabetic Macular Edema (DME)
5.5.6. Treatable Cases of Diabetic Macular Edema (DME)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of Diabetic Macular Edema (DME)
5.6.3. Sub-Type Specific cases of Diabetic Macular Edema (DME)*
5.6.4. Sex- Specific Cases of Diabetic Macular Edema (DME)*
5.6.5. Diagnosed Cases of Diabetic Macular Edema (DME)
5.6.6. Treatable Cases of Diabetic Macular Edema (DME)
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of Diabetic Macular Edema (DME)
5.7.3. Sub-Type Specific cases of Diabetic Macular Edema (DME)*
5.7.4. Sex- Specific Cases of Diabetic Macular Edema (DME)*
5.7.5. Diagnosed Cases of Diabetic Macular Edema (DME)
5.7.6. Treatable Cases of Diabetic Macular Edema (DME)
6. Unmet Needs
7. Marketed Drugs
7.1. Drug 1
7.1.1. Product Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Safety and Efficacy
7.1.5 Side-Effects
7.1.6. Product Profile
7.1.7. Sales
7.1.8. Patent Data
8. Emerging Drugs
8.1. Drug 1
8.1.1. Product Description
8.1.2. Clinical Trial Information and Results
8.1.3. Product Development Activity
8.1.4. Regulatory Milestones
8.1.5. Product Profile
8.1.6. Expected Launch Date
9. Country Specific Market Analysis
9.1. 7 Major Market Analysis
9.1.1. 7 Major Market Size
9.1.2. Therapy Wise Market Size
9.2. United States Market Analysis
9.2.1. United States Market Size
9.2.2. Therapy Wise Market Size
9.3. Germany Market Analysis
9.3.1. Germany Market Size
9.3.2. Therapy Wise Market Size
9.4. France Market Analysis
9.4.1. France Market Size
9.4.2. Therapy Wise Market Size
9.5. United Kingdom Market Analysis
9.5.1. United Kingdom Market Size
9.5.2. Therapy Wise Market Size
9.6. Spain Market Analysis
9.6.1. Spain Market Size
9.6.2. Therapy Wise Market Size
9.7. Italy Market Analysis
9.7.1. Italy Market Size
9.7.2. Therapy Wise Market Size
9.8. Japan Market Analysis
9.8.1. Japan Market Size
9.8.2. Therapy Wise Market Size
10. Market Drivers
11. Market Barriers
12. Market Opportunities
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com